Ingenus v. Nevakar: Cyclophosphamide Patent Resolved by Consent Judgment in 116 Days
Ingenus Pharmaceuticals and Leiutis Pharmaceuticals sued Nevakar Injectables and Endo Ventures in the District of New Jersey over US10993952B2, covering stable ready-to-use cyclophosphamide liquid formulations. The case concluded by consent judgment just 116 days after filing — an unusually swift resolution for pharmaceutical patent litigation.
Pharma patent clash over cyclophosphamide formulations ends swiftly
On 30 December 2022, Ingenus Pharmaceuticals, LLC and co-plaintiff Leiutis Pharmaceuticals, LLP filed a patent infringement action in the U.S. District Court for the District of New Jersey against Nevakar Injectables, Inc. and Endo Ventures, Ltd. The asserted patent, US10993952B2, covers stable ready-to-use cyclophosphamide liquid formulations — a clinically important oncology injectable product. The case was assigned Case No. 3:22-cv-07603.
The recorded basis of termination is Consent Judgment. The docket order states that, pursuant to Rule 41(a)(1)(ii) of the Federal Rules of Civil Procedure, the plaintiffs and Nevakar Injectables, Inc. stipulated and agreed that all claims in the action are dismissed without prejudice. The specific terms underlying the consent judgment are not disclosed in the available public record.
Resolution within 116 days of filing is notably rapid for pharmaceutical patent litigation in the District of New Jersey, a venue accustomed to protracted Hatch-Waxman and specialty-pharma disputes. The speed suggests the parties reached agreement before substantive motion practice or claim construction proceedings commenced. What drove the early resolution — whether commercial, licensing, or otherwise — is not disclosed in the available public record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 116 days
116 days from filing to consent judgment — well below the median for pharma patent cases in D.N.J.
US10993952B2 — Stable ready-to-use cyclophosphamide liquid formulations
If your R&D or product team is developing, manufacturing, or commercialising any stable ready-to-use cyclophosphamide liquid injectable, US10993952B2 is a live enforcement risk. This case demonstrates that the patent holders are willing to assert the patent in federal court and did so against both formulators and commercial partners. A freedom-to-operate analysis is advisable before market entry or expansion in this product category.
Official order — verbatim text
The recorded basis of termination is Consent Judgment. The docket order states a Rule 41(a)(1)(ii) stipulated dismissal without prejudice signed by counsel for Ingenus, Leiutis, and Nevakar Injectables. These two characterisations are reported as-is from the record; the specific terms agreed between the parties are not disclosed in the available public record.
Consent judgment: what the agreed resolution means for both parties
What a consent judgment means in practice
A consent judgment is a binding, court-entered judgment on terms agreed by the parties. It is not merely a voluntary dismissal — the court formally enters judgment, giving it the force of a judicial order enforceable by the court. Here, the procedural vehicle was a Rule 41(a)(1)(ii) stipulation, but the recorded basis of termination is Consent Judgment. The specific terms agreed between the parties are not disclosed in the available public record.
Court-entered, binding resolutionIngenus and Leiutis: patent survives, dispute resolved
For Ingenus Pharmaceuticals and Leiutis Pharmaceuticals, the consent judgment closes this particular action. US10993952B2 was neither invalidated nor adjudicated on the merits in this proceeding, meaning the patent remains in force and available for future enforcement. The specific terms governing any ongoing commercial or licensing relationship with Nevakar are not disclosed in the available public record.
Patent validity not adjudicatedNevakar and Endo Ventures: litigation risk closed at speed
Nevakar Injectables and Endo Ventures achieved an early exit from litigation before claim construction or substantive merits proceedings. The consent judgment ends the action as a formal court matter. What obligations, if any, Nevakar or Endo accepted as part of the agreed resolution are not disclosed in the available public record.
Early exit before merits proceedingsCyclophosphamide injectables: IP risk remains live for competitors
US10993952B2 covering stable ready-to-use cyclophosphamide liquid formulations was not invalidated or narrowed in this proceeding. Any manufacturer or developer of competing cyclophosphamide injectable formulations should treat this patent as an active enforcement risk. The swift resolution and absence of any public invalidity finding strengthens the practical enforceability signal of this patent in the specialty injectables space.
Active enforcement risk for sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Ingenus Pharmaceuticals, LLC | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Leiutis Pharmaceuticals, LLP | Company | Search in Eureka ↗ |
| Defendant | Nevakar Injectables, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Endo Ventures, Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Gregory D. Miller | Attorney | Counsel for Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Rivkin Radler LLP | Law Firm | Representing Ingenus Pharmaceuticals, LLCSearch in Eureka ↗ |
| Defendant counsel | Darren M. Geliebter | Attorney | Counsel for Nevakar Injectables, Inc.Search in Eureka ↗ |
| Defendant law firm | Lombard & Geliebter LLP | Law Firm | Representing Nevakar Injectables, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the cyclophosphamide injectables patent space
Forward-looking patent and R&D intelligence derived from the Ingenus v. Nevakar dispute — relevant to formulators, oncology developers, and IP teams in the specialty injectables sector.
Ingenus and Leiutis: mapping the cyclophosphamide patent family
US10993952B2 may be one asset in a broader Leiutis/Ingenus portfolio covering cyclophosphamide and related oncology injectables. Co-plaintiff enforcement suggests a co-ownership or licensing structure. Mapping the full family — including continuations, divisionals, and related applications — is essential for any competitor or potential licensee in this space.
Portfolio mapping priorityFiling trends in stable ready-to-use injectable formulations
The ready-to-use injectable sector has seen accelerating patent activity as developers seek clinical and operational advantages over lyophilised and reconstituted products. Cyclophosphamide is one of several oncology agents targeted by RTU formulation patents. Tracking filing trends in stabilisation technologies — including pH control, co-solvent systems, and preservative-free approaches — reveals where competitive IP is accumulating.
Rising RTU filing activityNevakar's formulation patent strategy in specialty injectables
Nevakar Injectables has positioned itself as a specialty injectable developer. Understanding its own patent filings and formulation IP — independent of this litigation — reveals whether it has defensive or offensive IP assets in adjacent injectable categories. This analysis helps competitors and partners assess Nevakar's long-term IP posture in the RTU injectables market.
Nevakar portfolio intelligenceDesign-around and adjacent opportunities near US10993952B2
With US10993952B2 actively enforced, R&D teams developing RTU cyclophosphamide products should explore formulation approaches outside the patent's claim scope — alternative stabilising agents, delivery systems, or concentration ranges. Adjacent white space in related alkylating agent formulations may also offer patentable and commercially viable product opportunities.
Formulation white spaceSimilar pharmaceutical formulation patent cases in D.N.J.
Explore related patent infringement actions involving injectable pharmaceutical formulations litigated in the District of New Jersey — a key venue for specialty pharma IP disputes.
What this case signals for the specialty injectables IP landscape
A swift consent judgment over a cyclophosphamide formulation patent sends a clear signal about enforcement posture in the ready-to-use injectables sector.
US10993952B2 remains enforceable: treat it as an active FTO risk
No invalidity finding, no claim narrowing, no merits adjudication occurred. The patent emerged from this litigation fully intact. Companies developing or manufacturing stable ready-to-use cyclophosphamide liquid formulations should run a current FTO analysis against US10993952B2 before entering or expanding in this product category.
Speed of resolution suggests early negotiating leverage for patent holder
A 116-day resolution in a D.N.J. pharmaceutical patent case — before claim construction proceedings — is consistent with defendants choosing early resolution over prolonged litigation risk. This pattern typically signals that the patent holder's enforcement position was credible enough to bring both defendants to the table quickly. Monitor Ingenus and Leiutis for further enforcement actions in the injectables space.
Ingenus v Nevakar — key questions answered
The recorded basis of termination is Consent Judgment. The case was filed on 30 December 2022 and closed on 25 April 2023, 116 days later. The docket order reflects a Rule 41(a)(1)(ii) stipulated dismissal without prejudice signed by counsel for Ingenus, Leiutis, and Nevakar. The specific terms of the consent judgment are not disclosed in the available public record.
The asserted patent is US10993952B2 (application number US15/551507), which covers stable ready-to-use cyclophosphamide liquid formulations. Cyclophosphamide is an alkylating chemotherapy agent; the patent addresses stable pre-mixed liquid forms suitable for direct injection, eliminating the need for reconstitution at point of care.
Plaintiffs are Ingenus Pharmaceuticals, LLC and Leiutis Pharmaceuticals, LLP, represented by Gregory D. Miller of Rivkin Radler LLP. Defendants are Nevakar Injectables, Inc. and Endo Ventures, Ltd., represented by Darren M. Geliebter of Lombard & Geliebter LLP. The case was litigated in the U.S. District Court for the District of New Jersey.
No. The patent was not adjudicated on the merits in this proceeding. There was no invalidity finding, no claim narrowing, and no inter partes review outcome recorded in connection with this case. US10993952B2 remains in force and is available for future enforcement by its holders.
A 116-day resolution in a pharmaceutical patent case in D.N.J. — before claim construction proceedings — is notably rapid. This is consistent with the parties reaching agreement before substantive litigation costs accumulated. What specifically drove the early resolution is not disclosed in the available public record. It does suggest neither party sought a prolonged merits battle at this stage.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.